URGN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

41.45M

+68.74%

-0.489

-38.93%

43.66M

+115.55%

-0.507

-44.93%

53.26M

+119.93%

-0.355

-66.19%

Estimates Revision

The market is revising Downward the revenue expectations for UroGen Pharma Ltd. (URGN) for FY2025, with the revenue forecasts being adjusted by -7.42% over the past three months. During the same period, the stock price has changed by 26.45%.

Revenue Estimates for FY2025

Revise Downward

-7.42%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+2.48%

In Past 3 Month

Stock Price

Go Up

+26.45%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast URGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for URGN is 39.40 USD with a low forecast of 31.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 22.850

Low

31.00

Averages

39.40

High

55.00

Current: 22.850

Low

31.00

Averages

39.40

High

55.00

Piper Sandler

Overweight

initiated

$36

2025-08-19

Reason

Piper Sandler

Price Target

$36

2025-08-19

initiated

Overweight

Reason

As previously reported, Piper Sandler initiated coverage of UroGen Pharma with an Overweight rating and $36 price target. Investors are starting to gain more confidence in the Zusduri launch, but the firm thinks the Street still underestimates peak sales potential in LG-IR-NMIBC and overestimates intellectual property risk to the -102/-103 franchise, the analyst contends. The firm sees early commercial launch datapoints, combined with updates from the Phase 3 UTOPIA trial of UGN-103, driving "meaningful upside" over the next 12-18 months.

Piper Sandler

NULL -> Overweight

initiated

$36

2025-08-18

Reason

Piper Sandler

Price Target

$36

2025-08-18

initiated

NULL -> Overweight

Reason

Piper Sandler initiated coverage of UroGen Pharma with an Overweight rating and $36 price target.

H.C. Wainwright

Buy

downgrade

$50 -> $40

2025-08-11

Reason

H.C. Wainwright

Price Target

$50 -> $40

2025-08-11

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on UroGen Pharma to $40 from $50 and keeps a Buy rating on the shares. The firm revised long-term sales projections post the Q2 report.

H.C. Wainwright

Neutral -> Buy

upgrade

$50

2025-06-17

Reason

H.C. Wainwright

Price Target

$50

2025-06-17

upgrade

Neutral -> Buy

Reason

Guggenheim

NULL -> Buy

upgrade

$15 -> $30

2025-06-13

Reason

Guggenheim

Price Target

$15 -> $30

2025-06-13

upgrade

NULL -> Buy

Reason

Scotiabank

Outperform

upgrade

$23 -> $47

2025-06-13

Reason

Scotiabank

Price Target

$23 -> $47

2025-06-13

upgrade

Outperform

Reason

Scotiabank raised the firm's price target on UroGen Pharma to $47 from $23 and keeps an Outperform rating on the shares. The firm is increasing its FDA approval likelihood from 60% to 100% and raised its price target based on its current view of a peak ZUSDURI market opportunity of about $1B, the analyst tells investors.

Valuation Metrics

The current forward P/E ratio for Urogen Pharma Ltd (URGN.O) is -14.77, compared to its 5-year average forward P/E of -4.20. For a more detailed relative valuation and DCF analysis to assess Urogen Pharma Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.20

Current PE

-14.77

Overvalued PE

-1.52

Undervalued PE

-6.88

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.70

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-0.81

Undervalued EV/EBITDA

-8.60

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

4.33

Current PS

0.00

Overvalued PS

6.23

Undervalued PS

2.43

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 573.47% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 194.83% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 573.47% over the last month.

Sold

Bought

URGN News & Events

Events Timeline

No data

News

4.0

10-04NASDAQ.COM

D. Boral Capital Continues to Recommend Buying UroGen Pharma (URGN)

4.0

08-19SeekingAlpha

Summit Takes Neutral Stance on Risk/Reward Dynamics as Piper Launches Coverage on Biotech Cancer Stocks

4.0

08-11Benzinga

HC Wainwright & Co. Maintains Buy on UroGen Pharma, Lowers Price Target to $40

People Also Watch

Frequently Asked Questions

What is Urogen Pharma Ltd (URGN) stock price today?

The current price of URGN is 22.85 USD — it has increased 4.82 % in the last trading day.

What is Urogen Pharma Ltd (URGN)'s business?

UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

What is the price predicton of URGN Stock?

What is Urogen Pharma Ltd (URGN)'s revenue for the last quarter?

Urogen Pharma Ltd revenue for the last quarter amounts to 27.48M USD, increased 9.04 % YoY.

What is Urogen Pharma Ltd (URGN)'s earnings per share (EPS) for the last quarter?

Urogen Pharma Ltd. EPS for the last quarter amounts to -0.69 USD, increased 25.45 % YoY.

What changes have occurred in the market's expectations for Urogen Pharma Ltd (URGN)'s fundamentals?

How many employees does Urogen Pharma Ltd (URGN). have?

Urogen Pharma Ltd (URGN) has 235 emplpoyees as of December 16 2025.

What is Urogen Pharma Ltd (URGN) market cap?

Today URGN has the market capitalization of 1.07B USD.